The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

BACKGROUND: Bevacizumab, a VEGF‐A inhibitor, in combination with chemotherapy, has proven to increase progression‐free survival (PFS) and overall survival in multiple lines of therapy of metastatic colorectal cancer (mCRC). The angiogenic factor angiopoetin‐2 (Ang‐2) is associated with poor prognosi...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Oncologist
Main Authors: Bendell, Johanna C., Sauri, Tamara, Gracián, Antonio Cubillo, Alvarez, Rafael, López‐López, Carlos, García‐Alfonso, Pilar, Hussein, Maen, Miron, Maria‐Luisa Limon, Cervantes, Andrés, Montagut, Clara, Vivas, Cristina Santos, Bessudo, Alberto, Plezia, Patricia, Moons, Veerle, Andel, Johannes, Bennouna, Jaafar, van der Westhuizen, Andre, Samuel, Leslie, Rossomanno, Simona, Boetsch, Christophe, Lahr, Angelika, Franjkovic, Izolda, Heil, Florian, Lechner, Katharina, Krieter, Oliver, Hurwitz, Herbert
פורמט: Artigo
שפה:Inglês
יצא לאור: John Wiley & Sons, Inc. 2019
נושאים:
Gastrointestinal Cancer
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066709/
https://ncbi.nlm.nih.gov/pubmed/32162804
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0291
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים